ClinicalTrials.govpublic full text
Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
gastroesophageal reflux disease (gerd), gastroesophageal, reflux, disease, gerd, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 865116
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.